RGH 618

Drug Profile

RGH 618

Alternative Names: RGH-618

Latest Information Update: 18 Apr 2016

Price : $50

At a glance

  • Originator Gedeon Richter
  • Class
  • Mechanism of Action Metabotropic glutamate receptor 5 agonists; Metabotropic glutamate receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Anxiety disorders

Most Recent Events

  • 18 Apr 2016 Phase-I development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top